AVROBIO, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • AVRO
  • 1d-0.79%
  • 1w0.00%
  • 1m-3.08%
  • 1y33.62%
ATH
  • ATH Price$52.70
  • ATH Date2018-09-26
  • % since ATH-97.61%
  • % to ATH4,082.54%
ATL
  • ATL Price$0.58
  • ATL Date2023-05-17
  • % from ATL117.99%
  • Last Low Price$0.578
  • Last Low Date2023-05-17
  • % From Last Low117.99%
IPO
  • IPO Price$29.25
  • % Current ROI USD-95.69%
  • ATH Price$52.70
  • % ROI ATH 911,764.71%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="AVRO"]

Key Data [addtoany]

Current price $1.26
Sector Healthcare
Industry Biotechnology
Today's High/Low $1.28/$1.2415
Volume 203,318.00
Previous Close $1.27
52 Week High/Low $1.7/$0.57
Market Cap 56,994,804.00
P/E Ratio 4.7037
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.33
Annualized Dividend $0
$1.26
[addtoany]

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.
Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.
The company’s lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease.
It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity